Weaning Protocol for High-flow Nasal Oxygen Therapy in Intensive Care
Status:
Recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
High-flow nasal oxygen therapy (HFNO) is an oxygenation technique frequently used in
intensive care.
The main objective of our study is to show that the use of a protocol for weaning patients
off high-flow nasal oxygen therapy (HFNO) in the intensive care unit increases the
probability that patients will be weaned from HFNO at Day 7 post-randomisation.
This is a open-label multicentre randomised controlled trial conducted in two parallel
groups.
The primary endpoint is the success rate at Day 7, with success defined as "definitive"
weaning from HFNO, i.e. patients weaned from HFNO for more than 48 hours without recourse to
non-invasive ventilation (NIV) or intubation and still alive at Day 7.
The weaning protocol will be started as soon as the patient meets all the inclusion criteria,
considered to be the prerequisites for initiating weaning from HFNO. Patients will be
monitored until Day 28 maximum.